CRISPR, Star Trek-Like Testing Devices, and Antibiotic Resistance a Focus at Clinical Diagnostics Convention, According to Kalorama Information
ROCKVILLE, Md., July 27, 2017 /PRNewswire/ -- Say it three times fast: "Clustered regularly interspaced short palindromic repeats" —Or better known as CRISPR. This gene-editing technology will be a key feature of the world's largest gathering of lab pathologies and the vendors that service them, according to research firm Kalorama Information. There is a $28 billion market for CRISPR according to the firm's report. Kalorama has covered the American Association for Clinical Chemistry meeting for a decade and a half and notes this important development as a sign that gene editing is reaching mainstream testing.
Experts predict the first attempt to treat people will be for blood-related diseases. The idea is to use CRISPR in a way similar to a bone marrow transplant, but to correct someone's own blood-producing cells rather than implanting donated ones. Medicine aside, another issue is environmental: altering insects or plants in a way that ensures they pass genetic changes through wild populations as they reproduce. These engineered "gene drives" are in very early stage research, too, but one day might be used to eliminate invasive plants, make it harder for mosquitoes to carry malaria or even spread a defect that gradually kills off the main malaria-carrying species.
The 2017 AACC Clinical Lab Expo will take place at the San Diego Convention Center, July 30–August 3, and according to the organization, is the premier international forum for presenting groundbreaking advances in laboratory medicine. Kalorama Publisher Bruce Carlson will attend the meeting. The 69th AACC Annual Scientific Meeting will heavily feature gene editing technologies such as CRISPR with a talk by CRISPR co-inventor Jennifer Doudna, PhD, on the future of genome engineering with this revolutionary tool, as well as a plenary on the clinical lab's critical role in combating the antibiotic resistance crisis.
Other lectures will feature winning team of the Qualcomm Tricorder XPRIZE competition, Final Frontier Medical Devices, will present its real-life Star Trek tricorder for the first time at a U.S. scientific conference. The mobile health device, called DxtER, weighs no more than five pounds and is designed to enable consumers to monitor five real-time health vital signs and diagnose 34 diseases—and all without the help of a clinician. Final Frontier Medical Devices team member Philip Charron will discuss the technological innovations behind DxtER and answer questions from meeting attendees, who have the expertise needed to assess the science of DxtER and its potential impact on patient care.
The meeting of more than 750 exhibitors will display pioneering diagnostic technology at the 2017 AACC Clinical Lab Expo, including the latest in mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation. Top companies in the in vitro diagnostic market with large presence at this meeting include: Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, Danaher (and subsidiary companies Cepheid and Beckman Coulter), bioMerieux, Bio-Rad, Luminex, Sysmex, DiaSorin, Tosoh, Ortho Clinical Diagnostics, Seegene, Thermo Fischer and hundreds of other companies.
Kalorama Information's report, Gene Editing Markets, examines in detail these technologies, as well as the global industry, its structure and major trends affecting it, and provides revenue forecasts by technology, product type, application area, and geographic regions. Profiles of various competitors in this industry are also included in this report. The report can be found at: http://www.kaloramainformation.com/Gene-Editing-CRISPR-10347331/?productid=10347331.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare, as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.
Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.
Press Contact:
Bruce Carlson
212 807 2262
[email protected]
SOURCE Kalorama Information
Share this article